DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is a Healthcare company (Biotechnology) with a market capitalization of $452M. The Maz Rating grades it against the other companies in its sector.
DiaMedica Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.38, DiaMedica Therapeutics Inc. trades at 15.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -94.5%, return on invested capital of -143.8% and a free cash flow yield of -7.4%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 4.76. Over the past 52 weeks the share price ranged from $5.25 to $11.00, with a beta of 0.94.
DiaMedica Therapeutics Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, DiaMedica Therapeutics Inc. (DMAC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.23% / 30% · Interest income / Revenue 31400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.23% / 33% · Receivables / Mkt Cap (36m) 0.04% / 49% · Interest income / Revenue 31400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.23% / 33.33% · Receivables / Mkt Cap (24m) 0.04% / 33.33% · Interest income / Revenue 31400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.14% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.9% / 33.33% · Receivables / Avg Assets (4Q) 0.22% / 33.33% · Interest income / Revenue 31400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.5% / 33.33% · (Cash+Recv) / Total Assets 97.0% / 33.33% · Interest income / Revenue 31400000.0% / 5% | Fail |
No. As of September 2026, DiaMedica Therapeutics Inc. (DMAC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. DiaMedica Therapeutics Inc. is over the AAOIFI limit on Interest income / Revenue.
About 31400000.0% of each dividend: DiaMedica Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.